Table S1.
Baseline characteristics of favorable risk patients according to TKI responses
| All n ═ 109 | PFS < 36 months n ═ 80 (73.4%) (short-term responder) | PFS ≥ 36 months n ═ 29 (26.6%) (long-term responder) | P value | |
|---|---|---|---|---|
| Age median (range) | 59 (20–89) | 60 (20–89) | 53 (45–74) | 0.41 |
| Gender, n (%) male | 82 (75.2) | 58 (31.2) | 24 (82.7) | 0.24 |
| Histology, n (%) clear cell RCC | 89 (81.6) | 61 (76.2) | 28 (96.5) | 0.32 |
| Previous nephrectomy, n (%) Yes | 107 (98.1) | 78 (97.5) | 29 (100) | 0.39 |
| ECOG PS, n (%) ≥ 1 | 49 (44.9) | 38 (47.5) | 11 (37.9) | 0.34 |
| Sarcomatoid feature Yes, n (%) | 15 (13.7) | 9 (11.2) | 6 (20.6) | 0.72 |
| Metastatic sites, n (%) | ||||
| Lung | 71 (65.1) | 51 (63.7) | 20 (68.9) | 0.61 |
| Liver | 14 (12.8) | 13 (16.2) | 1 (3.4) | 0.07 |
| Nodal | 48 (44.0) | 38 (47.5) | 10 (34.4) | 0.22 |
| Bone | 31 (28.4) | 24 (30.0) | 7 (24.1) | 0.62 |
| Brain | 16 (14.6) | 15 (18.7) | 1 (3.4) | 0.04 |
| First-line therapy, n (%) | ||||
| Sunitinib | 78 (71.5) | 61 (76.2) | 17 (58.6) | 0.07 |
| Pazopanib | 31 (28.4) | 19 (23.7) | 12 (41.3) | |
| Line of therapy after TKI, n (%) > 1 | 55 (50.4) | 44 (55) | 11 (37.9) | 0.11 |
ECOG PS: Eastern Cooperative Oncology Group Performance Status scale; PFS: Progression-free survival; RCC: Renal cell carcinoma; TKI: Tyrosine kinase inhibitor.